CLAIMS

- 1. (currently amended) A composition including an effective amount of the polypeptide EEIIMD in the range of 2 μM to 10 μM, and a suitable amount of a fibrinolytic agent to induce the desired level of fibrinolytic activity without causing cranial hemorrhage in a subject suffering from ischemic stroke, acute maycardial infarction, pulmonary emboli, peripheral artery disease or deep vein thrombosis.
- 2. (original) The composition according to claim 1, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisolylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.
- 3. (cancelled)
- 4. (cancelled)
- 5. (cancelled)
- 6. (cancelled)
- 7. (currently amended) A method of enhancing the fibrinolytic activity of a fibrinolytic agent, [[by]] said method comprising administering an effective amount of the polypeptide EEIIMD in the range of 2 uM to 10 uM, and a suitable amount of a fibrinolytic agent to induce the desired level of fibrinolytic activity without causing cranial hemorrhage in a subject suffering from ischemic stroke, acute maycardial infarction, pulmonary emboli, peripheral artery disease or deep vein thrombosis.

- 8. (original) The method according to claim 7, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisolylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.
 - 9. (withdrawn) The composition according to claim 1, wherein the half-life of a fibrinolytic agent is prolonged by administering an effective amount of anti-LRP antibodies to induce the desired level of fibrinolytic activity without causing hemorrhage.
 - 10. (withdrawn) The composition according to claim 9, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, ateplase, rt-PA-derivatives, reteplase, lanoteplase, TNK-rt-PA, rt-PA derivatives, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.